Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Operating Margin: 2010-2025

Historic Operating Margin for Corcept Therapeutics (CORT) over the last 11 years, with Sep 2025 value amounting to 4.92%.

  • Corcept Therapeutics' Operating Margin fell 2061.00% to 4.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.85%, marking a year-over-year decrease of 1396.00%. This contributed to the annual value of 20.29% for FY2024, which is 195.00% down from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' Operating Margin is 4.92%, which was down 64.13% from 13.72% recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Operating Margin peaked at 37.69% during Q3 2021, and registered a low of 2.17% during Q1 2025.
  • Its 3-year average for Operating Margin is 17.26%, with a median of 20.09% in 2024.
  • In the last 5 years, Corcept Therapeutics' Operating Margin spiked by 906bps in 2021 and then tumbled by 2,061bps in 2025.
  • Over the past 5 years, Corcept Therapeutics' Operating Margin (Quarterly) stood at 37.10% in 2021, then plummeted by 1,527bps to 21.83% in 2022, then skyrocketed by 156bps to 23.39% in 2023, then slumped by 950bps to 13.89% in 2024, then slumped by 2,061bps to 4.92% in 2025.
  • Its Operating Margin was 4.92% in Q3 2025, compared to 13.72% in Q2 2025 and 2.17% in Q1 2025.